$TVTX
Travere Therapeutics, Inc. Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000143853318000028 Filed on August 03, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$40.71M	$41.34M	$38.80M
YoY Change	101665.0%	6.54%	16.48%
Cost Of Revenue	$1.133M	$1.178M	$797.0K
YoY Change	22.49%	47.8%	-21.94%
Gross Profit	$39.57M	$40.16M	$38.00M
YoY Change	-4571.53%	5.67%	17.69%
Gross Profit Margin	97.22%	97.15%	97.95%
Selling, General & Admin	$26.11M	$25.10M	$28.84M
YoY Change	5.05%	-12.95%	24.26%
% of Gross Profit	65.97%	62.5%	75.88%
Research & Development	$32.45M	$34.46M	$19.48M
YoY Change	65.47%	76.88%	10.22%
% of Gross Profit	82.0%	85.81%	51.26%
Depreciation & Amortization	$4.800M	$4.640M	$4.440M
YoY Change	3.9%	4.5%	11.84%
% of Gross Profit	12.13%	11.55%	11.68%
Operating Expenses	$76.29M	$62.90M	$52.40M
YoY Change	49.74%	20.04%	17.25%
Operating Profit	-$35.58M	-$21.56M	-$13.60M
YoY Change	235.44%	58.55%	19.5%
Interest Expense	-$2.533M	-$1.057M	-$658.0K
YoY Change	283.79%	60.64%	347.62%
% of Operating Profit
Other Income/Expense, Net	-$18.52M	-$602.0K	-$1.556M
YoY Change	120.22%	-61.31%	-116.53%
Pretax Income	-$54.10M	-$22.16M	-$15.15M
YoY Change	184.49%	46.25%	-27.13%
Income Tax	$415.0K	$167.0K	-$1.925M
% Of Pretax Income
Net Earnings	-$54.52M	-$22.33M	-$13.23M
YoY Change	206.37%	68.79%	-1.3%
Net Earnings / Revenue	-133.93%	-54.02%	-34.1%
Basic Earnings Per Share	-$1.34	-$0.56	-$0.34
Diluted Earnings Per Share	-$1.34	-$0.56	-$0.34
COMMON SHARES
Basic Shares Outstanding	40.43M shares	39.94M shares	39.04M shares
Diluted Shares Outstanding			39.04M shares

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$350.9M	$255.7M	$296.0M
YoY Change	15.47%	-13.61%	33.62%
Cash & Equivalents	$154.8M	$89.31M	$89.27M
Short-Term Investments	$196.1M	$166.4M	$206.7M
Other Short-Term Assets	$5.600M	$5.500M	$6.000M
YoY Change	115.38%	-8.33%	-49.58%
Inventory	$5.129M	$5.388M	$4.369M
Prepaid Expenses
Receivables	$13.45M	$12.32M	$13.32M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$503.0M	$278.9M	$319.7M
YoY Change	54.6%	-12.75%	6.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.323M	$3.455M	$2.540M
YoY Change	22.3%	36.02%	566.67%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M
YoY Change
Other Assets	$7.393M	$5.351M	$3.628M
YoY Change	4.11%	47.49%	95.16%
Total Long-Term Assets	$213.2M	$212.2M	$187.5M
YoY Change	9.24%	13.2%	-19.82%
TOTAL ASSETS
Total Short-Term Assets	$503.0M	$278.9M	$319.7M
Total Long-Term Assets	$213.2M	$212.2M	$187.5M
Total Assets	$716.2M	$491.1M	$507.1M
YoY Change	37.59%	-3.15%	-5.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.314M	$7.847M	$9.076M
YoY Change	26.38%	-13.54%	44.41%
Accrued Expenses	$43.35M	$35.27M	$27.60M
YoY Change	34.4%	27.8%	19.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$22.40M	$45.40M
YoY Change
Total Short-Term Liabilities	$99.87M	$103.5M	$79.63M
YoY Change	19.03%	29.98%	-0.55%
LONG-TERM LIABILITIES
Long-Term Debt	$192.8M	$0.00	$44.70M
YoY Change	329.4%	-100.0%	1.36%
Other Long-Term Liabilities	$4.885M	$4.880M	$3.851M
YoY Change	28.28%	26.72%	51.14%
Total Long-Term Liabilities	$4.885M	$4.880M	$3.851M
YoY Change	28.28%	26.72%	51.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$99.87M	$103.5M	$79.63M
Total Long-Term Liabilities	$4.885M	$4.880M	$3.851M
Total Liabilities	$397.1M	$203.2M	$211.3M
YoY Change	83.86%	-3.86%	-3.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$262.6M	-$208.0M	-$142.2M
YoY Change	64.06%	46.26%	111.23%
Common Stock	$582.7M	$497.2M	$438.6M
YoY Change	25.27%	13.35%	14.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$319.1M	$288.0M	$295.8M
YoY Change
Total Liabilities & Shareholders Equity	$716.2M	$491.1M	$507.1M
YoY Change	37.59%	-3.15%	-5.03%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$54.52M	-$22.33M	-$13.23M
YoY Change	206.37%	68.79%	-1.3%
Depreciation, Depletion And Amortization	$4.800M	$4.640M	$4.440M
YoY Change	3.9%	4.5%	11.84%
Cash From Operating Activities	-$3.900M	-$2.760M	$5.470M
YoY Change	-162.9%	-150.46%	37.09%
INVESTING ACTIVITIES
Capital Expenditures	-$3.850M	-$3.730M	-$3.010M
YoY Change	2.94%	23.92%	30.3%
Acquisitions
YoY Change
Other Investing Activities	-$157.7M	$31.65M	$46.79M
YoY Change	-10340.26%	-32.36%	-2463.13%
Cash From Investing Activities	-$161.6M	$27.91M	$43.76M
YoY Change	7310.55%	-36.22%	-1120.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	231.0M	3.080M	-1.900M
YoY Change	3861.58%	-262.11%	-0.52%
NET CHANGE
Cash From Operating Activities	-3.900M	-2.760M	5.470M
Cash From Investing Activities	-161.6M	27.91M	43.76M
Cash From Financing Activities	231.0M	3.080M	-1.900M
Net Change In Cash	65.51M	28.23M	47.33M
YoY Change	565.08%	-40.35%	-2241.63%
FREE CASH FLOW
Cash From Operating Activities	-$3.900M	-$2.760M	$5.470M
Capital Expenditures	-$3.850M	-$3.730M	-$3.010M
Free Cash Flow	-$50.00K	$970.0K	$8.480M
YoY Change	-100.5%	-88.56%	34.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	13095000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40426729	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Retrophin, Inc.
	dei	Trading Symbol TradingSymbol	rtrx
CY2017Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1523000	USD
CY2018Q2	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1471000	USD
CY2017Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	6989000	USD
CY2018Q2	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	10742000	USD
CY2017Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3896000	USD
CY2018Q2	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	2964000	USD
CY2018Q2	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	12778000	USD
CY2017Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6429000	USD
CY2018Q2	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6403000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	9100000	USD
CY2018Q2	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	9500000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	80900000	USD
CY2018Q2	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	82000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Contingent Consideration BusinessCombinationOptionAgreementContingentConsideration	25000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold	1
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price BusinessCombinationOptionAgreementPurchasePrice	65000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transfered By Issuance Of Equity BusinessCombinationOptionAgreementPurchasePricePercentTransferedByIssuanceOfEquity	0.8
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transfered In Cash BusinessCombinationOptionAgreementPurchasePricePercentTransferedInCash	0.2
CY2018Q1	rtrx	Business Combination Option Agreement Share Price BusinessCombinationOptionAgreementSharePrice	21.40
CY2018Q1	rtrx	Business Combination Option Agreement Weighted Average Ten Day Share Price Which Requires All Cash Payment BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment	19.26
CY2017Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3284000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	6600000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	6628000	USD
CY2018Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	2159000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5786000	USD
CY2018Q2	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	255445	shares
	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	424057	shares
CY2017Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	726000	USD
CY2018Q2	rtrx	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	890000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8490000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1506000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1325000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	767000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8721000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8991000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	383000	USD
CY2017Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Loss Current DebtSecuritiesAvailableForSaleUnrealizedGainLossCurrent	302000	USD
CY2018Q2	rtrx	Debt Securities Available For Sale Unrealized Gain Loss Current DebtSecuritiesAvailableForSaleUnrealizedGainLossCurrent	451000	USD
CY2017Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainLossNoncurrent	424000	USD
CY2018Q2	rtrx	Debt Securities Availableforsale DebtSecuritiesAvailableforsale	166381000	USD
CY2018Q2	rtrx	Debt Securities Availableforsale Noncurrent DebtSecuritiesAvailableforsaleNoncurrent	51755000	USD
CY2017Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	5883000	USD
CY2018Q2	rtrx	Government Rebates Payable GovernmentRebatesPayable	6795000	USD
	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	651000	USD
	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	0	USD
CY2016Q4	rtrx	Legal Fee Judgment LegalFeeJudgment	2025000	USD
CY2018Q2	rtrx	Debt Securities Available For Sale Unrealized Gain Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainLossNoncurrent	439000	USD
CY2017Q4	rtrx	Debt Securities Availableforsale DebtSecuritiesAvailableforsale	201236000	USD
CY2017Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	123574000	USD
CY2018Q2	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	115077000	USD
CY2017Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	78388000	USD
CY2018Q2	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	52194000	USD
CY2017Q4	rtrx	Debt Securities Availableforsale Current DebtSecuritiesAvailableforsaleCurrent	123272000	USD
CY2018Q2	rtrx	Debt Securities Availableforsale Current DebtSecuritiesAvailableforsaleCurrent	114626000	USD
CY2017Q4	rtrx	Debt Securities Availableforsale Noncurrent DebtSecuritiesAvailableforsaleNoncurrent	77964000	USD
CY2018Q2	rtrx	Number Of Products Sold NumberOfProductsSold	3	product
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1000000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1000000	USD
	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	47500000	USD
	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	0	USD
	rtrx	Provision For Inventory ProvisionForInventory	-83000	USD
	rtrx	Provision For Inventory ProvisionForInventory	-378000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18938000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	7847000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13872000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12324000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-602000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-647000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36018000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35270000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2018Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7749000	USD
CY2018Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6895000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1015000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1152000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	471800000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	497183000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7239000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14332000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5426000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10035000	USD
CY2017Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4319000	USD
CY2018Q2	us-gaap	Assets Assets	491144000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	325807000	USD
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4495000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8694000	USD
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11300000	shares
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10500000	shares
CY2017Q4	us-gaap	Assets Assets	520346000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	278917000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	201962000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	167271000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	201236000	USD
CY2018Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	166381000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-553000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5563000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41002000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89266000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99394000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89305000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	48264000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10089000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1159424	shares
CY2018Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	735365	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39373745	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40370521	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39373745	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40370521	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13385000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24405000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21952000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40844000	USD
CY2017Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2018Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	45401000	USD
CY2018Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	74000000	USD
CY2017Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	45077000	USD
CY2018Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	797000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15710000	USD
CY2018Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2018Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1178000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2791000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5420000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	63000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-34000	USD
CY2017Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.127
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.141
CY2018Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.008
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.010
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018Q2	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2018Q2	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1300000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1280000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	20000	USD
CY2018Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	51046000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	59672000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	235863000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	247157000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	184817000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	187485000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	559000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-214000	USD
CY2017Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-183000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-259000	USD
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	2000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	24000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-305000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	936000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15154000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28308000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22162000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40311000	USD
CY2018Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1677000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1925000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3989000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	396000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3458000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2811000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4685000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1431000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	212000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	433000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	12000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-637000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-45000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2485000	USD
CY2018Q2	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	562500	USD
CY2017Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-658000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-790000	USD
CY2018Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-199000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	5351000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-557000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1916000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	520346000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85668000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	103497000	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	201236000	USD
CY2018Q2	us-gaap	Marketable Securities MarketableSecurities	166400000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	491144000	USD
CY2018Q2	us-gaap	Marketable Securities MarketableSecurities	166381000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1751000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	5388000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3435000	USD
CY2018Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3711000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	700000	USD
CY2018Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1400000	USD
CY2017Q2	us-gaap	Legal Fees LegalFees	2000000	USD
	us-gaap	Legal Fees LegalFees	2000000	USD
CY2018Q2	us-gaap	Legal Fees LegalFees	0	USD
	us-gaap	Legal Fees LegalFees	0	USD
CY2017Q4	us-gaap	Liabilities Liabilities	227212000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	203155000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	47893000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7056000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2059000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17494000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-13229000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-24319000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-22329000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40707000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1556000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-302000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-602000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-839000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	52398000	USD
	us-gaap	Operating Expenses OperatingExpenses	100426000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	62897000	USD
	us-gaap	Operating Expenses OperatingExpenses	119241000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13598000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-28006000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21560000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39472000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5556000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5351000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	27000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	173000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	375000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-161000	USD
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3112000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3902000	USD
CY2018Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3479000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2472000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4880000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-197000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-537000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	382000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	508000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-403000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-282000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	3254000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	7947000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	36213000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	29519000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	29700000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	15000000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6278000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11389000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1056000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	601000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2906000	USD
CY2017Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2842000	USD
CY2018Q2	us-gaap	Prepaid Taxes PrepaidTaxes	2613000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2140000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	800000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	43940000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	63565000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3003000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6890000	USD
CY2018Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1500000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2100000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3230000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3455000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	410000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-13000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	500000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	500000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	72420000	USD
CY2018Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	41337000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	79769000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28835000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19482000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40342000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34460000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59096000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	3549000	USD
CY2018Q2	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177655000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208046000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38800000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	72420000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41337000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79769000	USD
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	38800000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	51950000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25100000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	51568000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14332000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10160000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4600000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.40
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	293134000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	287989000	USD
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39041145	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38545982	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40061045	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39641334	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company is developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">pantothenate kinase-associated neurodegeneration (“PKAN”). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include dystonia, dysarthria, rigidity, retinal degeneration, and severe digestive problems. There are currently no viable treatment options for patients with PKAN. Fosmetpantotenate is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan (RE-021) is an investigational product candidate which acts as both a potent </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">angiotensin receptor blocker (“ARB”), as well as a selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A. The Company secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). The Company is developing sparsentan as a treatment for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">▪</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Focal segmental glomerulosclerosis ("FSGS")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is a leading cause of end-stage renal disease and nephrotic syndrome (“NS”). There are no U.S. Food and Drug Administration ("FDA") approved pharmacologic treatments for FSGS and off-label resources are limited to ACE/ARBs, steroids, and immunosuppressant agents, which are effective in only a subset of patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">▪</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Immunoglobulin A nephropathy ("IgAN")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is characterized by hematuria, proteinuria, and variable rates of progressive renal failure. There is no FDA approved treatment for IgAN.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a party to a joint development agreement with Censa Pharmaceuticals Inc. ("Censa"), a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate sepiapterin ("CNSA-001") for the treatment of phenylketonuria ("PKU"). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin ("BH4") with the potential to provide improved phenylalanine ("Phe") reduction in patients with PKU when compared to BH4.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">PKU is a rare, genetic metabolic condition in which the body cannot breakdown Phe due to a missing or defective phenylalanine hydroxylase ("PAH") enzyme. High Phe levels can lead to developmental and physical growth delay, executive function impairment, seizures, and microcephaly caused by toxic Phe accumulation in the brain.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is party to a three-way Cooperative Research and Development Agreement ("CRADA") with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation NGLY1.org to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for N-glycanase deficiency ("NGLY1").</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">NGLY1 is an extremely rare genetic disorder believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition has been characterized by symptoms such as developmental delays, seizures, complex hyperkinetic movement disorders, diminished reflexes and an inability to produce tears. There are no approved therapeutic options for NGLY1 deficiency, and current therapeutic strategies are limited to symptom management.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). The Company obtained the rights to L-UDCA in 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company sells the following </font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">three</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"> products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal® (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam® (cholic acid capsules) is approved in the United States (approved and marketed in Europe for select indications as Kolbam) for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola® (tiopronin tablets) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table></div>

Files In Submission

Name	View Source	Status
0001438533-18-000028-index-headers.html	Edgar Link	pending
0001438533-18-000028-index.html	Edgar Link	pending
0001438533-18-000028.txt	Edgar Link	pending
0001438533-18-000028-xbrl.zip	Edgar Link	pending
ex06302018311.htm	Edgar Link	pending
ex06302018312.htm	Edgar Link	pending
ex06302018321.htm	Edgar Link	pending
ex06312018322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelineq22018a03.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20180630.xml	Edgar Link	completed
rtrx-20180630.xsd	Edgar Link	pending
rtrx-20180630x10q.htm	Edgar Link	pending
rtrx-20180630_cal.xml	Edgar Link	unprocessable
rtrx-20180630_def.xml	Edgar Link	unprocessable
rtrx-20180630_lab.xml	Edgar Link	unprocessable
rtrx-20180630_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics, Inc. Stock $tvtx

2018 Q3 Form 10-Q Financial Statement

#000143853318000028 Filed on August 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics, Inc. Stock $tvtx

2018 Q3 Form 10-Q Financial Statement

#000143853318000028 Filed on August 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics, Inc. Stock $tvtx